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treatments inducing various levels of immunodeﬁciency. Acute
viral infections may then be attributed either to transfusion-
transmitted infection (TTI) or reactivation of a past infection.
Methods: A patient with chronic lymphocytic leukemia (CLL)
who had >250 blood donor exposures developed acute Hepatitis
B virus (HBV) infection. Routine donor testing for HB core anti-
bodies (anti-HBc) was in place in the relevant period and investi-
gations undertaken on the blood donors were negative.
Results: Review of historical, molecular, and antigenic evidence
demonstrated reactivation of a recovered HBV infection dating
>30 years and the selection of a rare escape mutant that brieﬂy
replicated and caused acute liver disease. This mutant was unre-
active with several HBsAg assays and poorly reactive with an HBV
vaccine plasma. Correcting the C139Y substitution by site direc-
ted mutagenesis of recombinant surface proteins re-established
assay reactivity.
Conclusions: Fludarabine, but not Chlorambucil, appeared sufﬁ-
ciently immunosuppressive to trigger reactivationdespite low lev-
els of neutralizing antibodies. Differentiating between TTI and
reactivation of HBV becomesmore challengingwith the increasing
frequency of immunocompromised blood recipients. Chemother-
apy with Fludarabine alone should be considered as carrying high
risk of viral reactivation. Pre-treatment testing and peripheral
blood sample archiving may be indicated in HBsAg negative
patients.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
In hematology, for patients receiving aggressive chemotherapy,
reactivation of HBV is well described in populations with high
endemicity and patients who are healthy HBV carriers [HepatitisJournal of Hepatology 20
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may be exposed to a large number of blood donors over the
course of their treatment, acute HBV infection tends to be attrib-
uted to transfusion, notwithstanding the very low risk of transfu-
sion-transmitted HBV (TT-HBV). An increasing body of evidence
suggests that common viruses such as parvovirus B19 and HBV
infections persist at very low levels after clinical recovery with
the development of neutralizing antibodies in sanctuaries such
as the bone marrow or the liver, respectively, but may be found
in plasma with sensitive genomic ampliﬁcation methods [3,4].
Reactivation of herpes viruses such as CMV has been described
abundantly in severe immunodeﬁcient patients receiving chemo-
therapy for cancer or organ and bone marrow transplantations.
Common reactivation of viral infections, which generate neutral-
izing humoral immunity, is not always considered [5,6]. Since
patients receiving chemotherapy often need transfusion, circum-
stances, in which TTI is suspected despite the high degree of
safety of blood components, are not uncommon. The differential
diagnosis between transfusion transmission and reactivation
becomes critical for medical and legal reasons.
We describe a case where, reactivation of HBV occurred in an
HBsAg negative patient treated with Fludarabine who had recov-
ered from acute infection over 30 years earlier and had received
HBV vaccine 18 months before this occurred.
Case report
In October 2004, theMunster Regional Transfusion Centre (MRTC),
of the Irish Blood Transfusion Service (IBTS) received notiﬁcation
of a suspected TT-HBV in a transfusion-dependent hematology
patient who had developed HBV serological markers. A look-back
was initiated to trace and test implicated donors. An investigation
into other possible causes was instigated concurrently.
This 54-year-old male, diagnosed with CLL in November 2001
was initially well maintained with intermittent alkylating cyto-
toxic chemotherapy (5 courses). In April 2003 he had a complete
course of HBV vaccination, as a member of a voluntary defence
force following which anti-HBs was detected. When his disease
progressed in November 2003, Fludarabine was instituted. In
March 2004 he was admitted with sepsis secondary to pancyto-
penia and bone marrow reserve was insufﬁcient to tolerate
further Fludarabine. He was ﬁrst transfused on March 16, 200410 vol. 53 j 780–787
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and intermittently thereafter, with both red cell and platelet
components becoming heavily transfusion dependant by July.
His clinical course was stormy, requiring broad-spectrum anti-
microbial therapy, (including treatment for CNS AFB). On admis-
sion in March 2004, ALT level was signiﬁcantly elevated at
104 IU/L, and remained so to October when MRTC was notiﬁed
(max 308 IU/l). Mild hyperbilirubinemia (29 lmol/L) persisted
over the same time period. Serological markers for HBV were
detected on the 29th October 2004, including HBsAg, anti-HBc,
(IgM negative), and HBe antigen with anti-HBs detected at
10.4 IU/L (Table 1). HAV serological markers were consistent with
past infection (anti-HAV total antibody positive/IgM negative). By
April 2005, the patient was HBsAg and HBV DNA negative, and
anti-HBc positive with undetectable anti-HBs.Methods
All implicated components transfused to the patient were identiﬁed by the hos-
pital blood bank and notiﬁed to MRTC. All donors were traced and deferred from
the active donor panel. Donors were advised of their possible implication in a sus-
pected TT-HBV and were invited to attend for HBV re-screening at an interval of
>6 months after the implicated donation. Donors were re-tested for HBV by
HBsAg (sensitivity <0.1 PEI units/ml) and anti-HBc by Abbott Prism Chemilumi-
nescence at MRTC. In a few cases an archive sample of the index donation was
tested for HBV DNA by PCR at University of Edinburgh.
The patient’s medical and laboratory records were scrutinized and the patient
and family were interviewed. Family contacts were tested for serological or viro-
logical evidence of current or past Hepatitis B virus infection by HBsAg, anti-HBc,
HBe antigen (Abbott, Axym, Delkenheim, Germany), anti-HBs, and HBV DNA.
Patient and control samples
Plasma samples studied included two samples from chronically HBV infected
people (HBsAg positive, anti-HBc positive, negative for anti-HBs), one of whom
(Patient 1) was the brother-in-law of the index patient, the second an unrelated
donor (Patient 2), and both carried wild type genotype D strains. Plasma from two
laboratory workers vaccinated with HBV recombinant S protein (genotype A2)
were used as positive controls and samples from two blood donors negative for
all HBV markers were used as negative controls.
Viral DNA isolation and ampliﬁcation
Viral DNA was isolated and nested-PCR was used to amplify the S and BCP genes
as previously described [7].
HBV DNA quantiﬁcation
Viral DNA was quantiﬁed by QPCR using a TaqMan-based methodology as previ-
ously described [7]. The ﬂuorogenic probe was 50-labelled with Cy5 dye and 30-
labelled with Black Hole Quencher 2 (BHQ-2).
HBV sequencing and genotyping
Sequences of S and BCP/PC regions were obtained by direct sequencing of PCR
products and phylogenetic analyses were performed as described previously
[7]. In addition, full genome of the index patient was ampliﬁed as previouslyTable 1. HBV markers in index patient, index patient spouse, Patients
Patient HBsAg HBeAg HBV DNA load (IU/ml) HBV
Index 4-2004 Negative ND
10-2004 Positive Positive 103 D
4-2005 Negative Negative
Index spouse1 Negative Negative
Patient 1, 2004 Positive 6.3  105 D
Patient 2, 2004 Positive 2.4  103 D
1 From an archived sample collected in 2000.
Journal of Hepatology 201described, cloned, and two clones were sequenced using a series of seven primer
pairs covering the complete HBV genome [7]. For comparison purposes, samples
from Patients 1 and 2 were extracted for DNA, ampliﬁed and sequenced in the
pre-S/S and S regions (1420 nucleotides). Phylogenetic analysis was performed
by using PAUP* version 1.0 b10 and the neighbour-joining algorithm based on
Kimura two-parameter distance estimation, ignoring all positions with gaps in
pairwise comparisons. To conﬁrm reliability of phylogenetic tree topologies,
bootstrap reconstruction was carried out 1000 times and bootstrap values >75%
were considered signiﬁcant.Preparation of recombinant S proteins
The S gene of controls and the index patient samples were ampliﬁed by PCR. The
sense primer was designed to include a SnaB1 site and the ATG start codon in the
context of a Kosac sequence: ACTCTACGTAACCATGGARAACAYMACATCAGGA. The
antisense primer included the EcoRI site, a six histidine tag, ﬂag tag, a strep tag II
sequences, the stop codon, and the S gene: CCAGGGAATTCTCATTTTTCGAACTG
CGGGTGGCTCCACTTGTCGTCATCGTCCTTGTAGTCATGGTGATGGTGATGATGGGCCG
CAATGTATACCCAVAGACABAAGAA. Ampliﬁcation was performed in a mix con-
taining 1 Expand High Fidelity buffer, 2.5 mM MgCl2, 0.20 mM dNTPs, 0.4 lM
each primer, and 2.5 U of Expand High Fidelity Enzyme (Roche, Mannheim, Ger-
many). Ampliﬁcation was started at 94 C for 5 min followed by 30 cycles of 94 C
for 40 s, 50 C for 40 s, and 72 C for 1 min, and a ﬁnal extension at 72 C for
10 min. The PCR product of the S gene was inserted into pPIC3.5K (Invitrogen,
Paisley, UK). The recombinant vector was then expressed in Pichia pastoris accord-
ing to the manufacturer’s instructions (Invitrogen). The selected colonies were
grown in 1 L of buffered minimal glycerol (BMGY) medium [1% (w/w) yeast
extract, 2% (w/w) peptone, 1.34% (w/w) yeast nitrogen base, 0.4 mg L1 biotin,
and 100 mM potassium phosphate (pH 6.0) 1% (v/v) glycerol] until optical density
at 600 nm (OD600) was >6. Cells were induced by 1% methanol by replacing the
BMGY by buffered minimal methanol (BMMY) medium [1% yeast extract, 2% pep-
tone, 1.34% yeast nitrogen base, 0.4 mg/ml biotin, and 100 mM potassium phos-
phate (pH 6.0) 1% methanol]. Methanol was added at a concentration of 1% every
24 h during the induction phase (72 h). Cultures were centrifuged and pelleted
yeast cells were re-suspended in a 25 mM of Tris buffer (pH 7.6) and submitted
to high pressure (30 kpsi) cell disruption in a cell disrupter system (Constant Sys-
tem, Daventry, UK). The lysates were further clariﬁed by centrifugation. The
supernatant was subjected to ultraﬁltration through 300,000 nominal molecular
weight cut-off (NMWC) hollow ﬁbers (GE Healthcare, Slough, UK) post-clariﬁca-
tion using 45-lm ﬁlter. HBsAg particles were further puriﬁed by immuno-afﬁnity
using an anti-Flag M2 afﬁnity gel (Sigma, Gillingham, UK) eluted with 100 lg/ml
of ﬂag peptide (Sigma) in TBS. The eluted proteins were analyzed with 12% SDS–
PAGE followed by staining with Coomassie brilliant blue and detection by Wes-
tern blot with monoclonal anti-Flag M2 antibody (Sigma). Concentration of
HBsAg protein was determined by densitometry using known concentration of
bovine serum albumin as standard (http://rsbweb.nih.gov/ij/). An additional,
more speciﬁc, method was used to quantify and normalize the recombinant S
protein based on StrepTactin-coated plates (IBA, Gottingen, Germany).
Site directed mutagenesis by overlap extension PCR
Site directed mutagenesis (SDM) was carried out using two-step PCR procedure
to restore the cysteine 139 mutation that was suspected to alter HBsAg conforma-
tion and assay recognition. Two reactions were performed with a primer pair
[PIC3.5K-F/SDM-R(TCCGTCCGAAGGTTTGGTACAGCAACAGGA), PIC3.5K-R/SDM-
F(562-TCCTGTTGCTGTACCAAACCTTCGGACGGA-591)] using 50 ng of the original
mutated DNA. To obtain full-length mutated fragment, an equimolar concentra-
tion (100 ng) of the two PCR products was used as template in the second reac-
tion with PIC3.5K forward and reverse primers as described above. The PCR
product was cloned in PIC3.5 vector for expression in Pichia strain.1 and 2 (unrelated chronic infection).
genotype Anti-HBc Anti-HBe Anti-HBs (IU/L) ALT (IU/L)
Positive ND 104
Positive Negative 10.4 308
Positive Negative
Positive Positive 200 ND
Positive Negative
Positive ND ND
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Capture enzyme-linked immunosorbent assay (ELISA) of recombinant S proteins
StrepTactin-coated plates (96-well) were incubated with recombinant S protein
diluted with TBS buffer (25 mM Tris–HCl, 150 mM NaCl, 2 mM EDTA; pH 7.6) at
0.1 lg/wells (the saturation concentration for the StrepTactin plates) for 1 h at
37 C. The plates were washed ﬁve times with PBS/0.1% Tween 20 at room tem-
perature. Diluted monoclonal anti-Flag M2 antibody (1:5000) or plasma diluted
1:100 with TBS were incubated for 1 h at 37 C and tested in duplicate. After
washing with PBS/0.5% Tween 20, 100 ll of diluted horseradish peroxidase-con-
jugated anti-mouse (1:10,000) or anti-human Fc IgG monoclonal antibody
(Sigma, 1:50,000) were added per well and incubated at 37 C for 1 h. Plates were
washed with 0.3 ml of PBS/0.5% Tween 20 and 100 ll 3,39,5,59-tetramethylbenz-
idine (TMB) substrate (Pierce, Cramlington, UK) per well were added, followed by
incubation at room temperature in darkness for 20 min. The reaction was stopped
by the addition of 100 ll of 1 M sulfuric acid and the absorbance of each well was
read at 450 nm. The cut-off was determined as the mean absorbance of four anti-
HBV negative control samples plus six standard deviations. Sample/cut-off ratios
were calculated to express the reactivity of the samples: ratios above 1 were con-
sidered positive. An HBsAg standard curve was generated from the recombinant
HBsAg positive control (wild type strain) following detection with ﬂag antibody
to normalize the protein concentration between samples.
Antibody-capture ELISA with recombinant S proteins
The recombinant S proteins produced in addition to a commercially available
recombinant HBsAg (Aldevron, Fargo, USA) were used at 0.1 lg/wells to coat
96-well microplates overnight at 4 C. Plates were washed ﬁve times with
0.3 ml/well of PBS/0.1% Tween 20 and then blocked with 250 ll PBS/0.05% Tween
20/4% BSA at 37 C for 1 h, followed by ﬁve washes with 300 ll PBS/0.1% Tween
20 per well. Three monoclonal antibodies to HBsAg (Diagnostics for the Real
World Ltd., Sunnyvale, CA, USA) and one animal polyclonal antibody (Abcam,
Cambridge, UK) were serially diluted 1:1000, 1:5000, 1:10,000, 1:50,000 in PBS/
0.05% Tween 20/1% BSA and 100 ll of each dilution were added to the wells
and incubated for 1 h. One hundred microliters of 1:10,000 diluted secondary
antibody labelled with horse radish peroxidase (HRP) were added and revealed
by TMB as described above.
Commercial HBsAg screening assays
Semi-puriﬁed recombinant HBsAg were tested at a concentration of 1 lg/ml with
four different commercial microplate EIAs and two lateral ﬂow rapid tests: MonoL-
isa AgHBs Plus (Bio-Rad, Marnes Ia Coquette, France), Hepanostika HBsAg Ultra
(bioMerieux, Marcy-I’Etoile, France) Abbott/Murex (Abbott, Delkenheim, Ger-
many), Bioelisa HBsAg Colour (Biokit, Barcelona, Spain), Determine HBsAg (Abbott,
Delkenheim, Germany) and DRW-HBsAg (DRW, Sunnyvale, USA), respectively.Results
The presence of anti-HBc prior to the acute episode of Hepatitis B
during Fludarabine chemotherapy suggested prior exposure to
HBV. As a result, investigation of the past history of the index
patient was conducted. It uncovered evidence consistent with
past HBV infection. Serological testing of 09 and 13 April 2004
samples revealed anti-HBc positive, HBsAg negative (anti-HBs
not tested). The patient had had an episode of icteric hepatitis
in 1975 and his spouse had an institutionalized sibling with
established chronic HBV carriage (Patient 1). She had donated
blood in 2000, prior to the introduction of anti-HBc blood dona-
tion screening and was found to be HBsAg negative. However,
current testing results were consistent with past HBV infection
and effective immunity (HBsAg neg, anti-HBs 200 IU/L, anti-HBc
pos, and anti-HBe positive). In addition the couple’s ﬁrst-born
child (DOB 1980) showed serological evidence of past infection
(HBsAg negative, anti-HBs, and anti-HBc positive) while their
younger child was seronegative. This historical data strongly sug-
gested that, in addition to his brother-in-law who had chronic782 Journal of Hepatology 201HBV infection (Patient 1), the index patient’s spouse also had
chronic HBV infection and transmitted HBV to both her husband
and ﬁrst-born child. She subsequently seroconverted to anti-HBs
and recovered from the infection, apparently spontaneously [4].
The index patient having been infected as an adult recovered
from the infection and 30 years later carried anti-HBc as the only
indication of the previous infection until vaccinated to HBV.
Although this patient’s history was highly suggestive of reac-
tivation, community-acquired infection was not completely
excluded. As a result, molecular evidence of relatedness between
the HBV strains infecting the index patient and the only remain-
ing family member with chronic infection, i.e. Patient 1, were
studied. Samples from both individuals as well as a sample from
an unrelated HBsAg-carrying blood donor from MRTC were sent
under code to the Cambridge Laboratory, and examined for viral
load, genotype and sequencing.
As shown in Fig. 1, the phylogenetic tree constructed with
1420 nucleotide pre-S/S sequences from the three patients and
selected references indicated that all three Irish patients carried
genotype D strains (sequence accession numbers for Index
GU570523, for Patient 1 GU570524, and for Patient 2
GU570526). It also showed that the index patient and Patient 1
carried HBV strains that were closer to each other than to other
strains although it was clustered with four other strains with a
bootstrap value of 81% (Fig. 1). In particular Patient 1 carried a
24-nucleotide deletion in two out of four sequenced clones in
the pre-S2 region (nt 31–54 from EcoR1 restriction site) that
was not present in the index patient strain. The two other clones
do not carry this deletion but have a mutation at the initiation
codon of pre-S2.
The fact that the index patient had developed acute HBV
infection despite having received HBV vaccine approximately
18 months prior to the acute episode and while carrying low lev-
els of anti-HBs generally considered protective of HBV infection
remained to be elucidated. This situation was compatible with
an escape mutant involved in the acute infection. To examine this
hypothesis, the S region sequences containing the major hydro-
philic region (MHR) from the index patient, Patients 1 and 2
strains were obtained and translated to compare amino acid
sequences. As shown in Fig. 2, the three strains substantially dif-
fered from each other. In particular, the index patient had a
C139Y substitution that was assumed to disrupt considerably
the presentation of the MHR loop 4 epitope. In addition, two sub-
stitutions were seen in loop 3: G130R and Y134N compared to
the Patient 2 reference strain and one in loop 1: P120S. These
substitutions were compatible with an escape mutant being
responsible for the acute HBV infection.
The escape mutant hypothesis was further explored by pre-
paring puriﬁed recombinant S protein from the index patient
and the genotype D control (Patient 2). The reactivity of these
two proteins was tested against the pre-acute HBV infection
plasma of the index patient and of two other vaccinated healthy
individuals, six commercial HBsAg assays and four monoclonal
or polyclonal antibodies to HBsAg. Results are summarized in
Table 2. The index patient recombinant S protein did not react
with the index patient plasma, with one of four HBsAg commer-
cial EIA, with two HBsAg rapid tests and was poorly reactive
with two of three monoclonal antibodies to MHR. However, this
heavily mutated protein remained strongly reactive with 2/4
commercial HBsAg EIA, one monoclonal and one polyclonal
antibodies. In contrast to the index sample, both controls0 vol. 53 j 780–787
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Fig. 1. Phylogenetic tree of the pre-S/S region of Index, Patients 1 and 2 HBV strain compared to genotype D and other genotype strains. The phylogenetic tree was
constructedwith a 1420 nucleotide sequences in the pre-S/S region of HBV. Phylogenetic analysis was performedwith the neighbour-joining algorithm based on Kimura two-
parameter distance estimationmethod. Only bootstrap valuesP75% are shown (1000 replicates). The GenBank accession numbers of Pro and Patients 1 and 2 are GU570523,
GU570524, and GU570526, respectively.
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Fig. 2. Amino acid sequence of the central part of MHR of three Irish genotype D patients and subgenotype D3 references. Index patient amino acid sequence is
aligned against Patient 2 sequence used as wild type subgenotype D1 reference. Patient 1 appears possibly related to the index strain and shows similarities with but also
considerable divergence from the index strain. Other subgenotype D3 reference strains are indicated by their GenBank accession number. Grey bars indicate antigenic loops
1–4 between cysteines 107 and 121, 121 and 124, 124 and 137, and 139 and 147, respectively.
Case Report(Patient 2 and Aldevron) reacted with all HBsAg commercial
EIAs and rapid tests as well as with all monoclonal or polyclonal
anti-HBs. The index patient protein was not as well recognized
as the genotype D control recombinant protein from Patient 2
and the genotype A2 commercial recombinant HBsAg by plas-
mas from vaccinated people (Table 2). However, plasma from
the index patient did not carry sufﬁcient level of anti-HBs to
react with any of these three recombinant antigens. This is
not particularly surprising since the level of anti-HBs detected
at the time of sample collection was very close to the cut-off
(10 IU/L) and when re-tested in 2009 with two commercial
anti-HBs assays were non-reactive. The absence of recognition
of this mutant antigen by three HBsAg screening assays, low
level of reactivity with one EIA and two monoclonal antibodies
(Ab1 and Ab2) and strong reactivity with only two commercial
HBsAg screening assay clearly indicated considerably modiﬁed
MHR epitopes.
When cysteine 139 mutation was corrected by SDM, the reac-
tivity of one commercial EIA and two rapid tests unable to detectTable 2. Detection of recombinant HBsAg with different plasmas, assay
Samples (dilution) Reactivity of recom
Index HBsAg C139 cor
Index plasma (1/100) Negative Negative
Patient 12 (1/100) Negative Negative
Patient 22 (1/100) Negative Negative
Donor 13 (1/100) Negative Negative
Donor 23 (1/100) Negative Negative
Vaccine 14 (1/100) 7.9 8.9
Vaccine 24 (1/100) 4.6 7.8
Microtiter EIA 1 Negative 7.3
Microtiter EIA 2 32.1 >50
Microtiter EIA 3 26.5 >50
Microtiter EIA 4 3.7 13.2
Rapid test 1 Negative Positive
Rapid test 2 Negative Positive
Monoclonal Ab1 (1/1000) 5.6 8.6
Monoclonal Ab2 (1/1000) 4.0 7.3
Monoclonal Ab3 (1/1000) 18.6 16.7
Polyclonal Ab (1/1000) 11.5 14.2
1 Since the commercial HBsAg did not carry strep tag II, HBsAg was directly coated at 1
Strep tag captured HBsAg explains the difference in S/CO levels.
2 Patients 1 and 2 were HBV chronic carriers with wild type genotype D strains.
3 Donors 1 and 2 were healthy and non-vaccinated to HBV.
4 Vaccines 1 and 2 were healthy laboratory workers vaccinated against HBV and carry
784 Journal of Hepatology 201the mutated S protein (EIA1 and EIA4) was restored (Table 2). The
S/CO of all other assays moderately or highly reactive with the
index recombinant protein was enhanced. All monoclonal anti-
bodies reacted strongly.
The accumulation of historical, phylogenetic, and S protein
studies concurred to support reactivation of an escape mutant
from recovered HBV infection 30 years earlier. However, the
look-back study of potentially implicated blood donors had been
put in motion. This onerous exercise identiﬁed and traced 268
donors to the 74 red cell and 46 pooled platelet components
transfused. One donor met re-instatement criteria at the time
of notiﬁcation. Subsequently a further 114 donors re-tested
HBV negative P6 months after their index donation while 29
additional donors re-tested HBV negativeP3 months after theirs.
In four cases where the donor never re-attended, the archive
donation samples tested negative for anti-HBc and HBV DNA.
Negative look-back information was available from 148/268
implicated donors when clear evidence of reactivation was
obtained and the look-back was closed.s or antibodies.
binant S protein expressed as sample/cut-off (S/CO)
rected Patient 2 HBsAg Aldevron HBsAg1
Negative Negative
Negative Negative
Negative Negative
Negative Negative
Negative Negative
9.9 18
9.9 10
36.4 30
36.9 >50
43.6 >50
42.2 20
Positive Positive
Positive Positive
26.8 18.1
25.1 52.6
27.1 70.7
18.7 9
lg/ml overnight at 4 C as described in Methods. This direct coating compared to
ing 68 IU/L and 18 IU/L anti-HBs, respectively.
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Discussion
Estimates of the residual risk of TT-HBV range from 1 in 50,000–
426,000 (UK) [8], 1 in 60–150,000 (US) [9], 1 in 400,000 [10]
(France) and 1 in >1 million (Australia) [11], without HBV Nucleic
Acid Testing (NAT). In the 5 years to end of 2004, testing of
219,677 donations at MRTC identiﬁed a single donor with sero-
logical evidence of HBV (<0.5/100,000 donations). All donations
to the IBTS since January 2002 were screened prospectively for
anti-HBc although less than 1% anti-HBc positive donations
may have detectable DNA, a proportion of which are potentially
infectious [12,13].
The residual risk therefore reﬂects either incident primary
infection window period (WP) donations or very rare cases of
‘occult’ Hepatitis B without anti-HBc with only viral DNA as a
marker of the infection [14]. The Serious Hazards of Transfusion
(SHOT)/Communicable Diseases Surveillance Centre (CDSC)
reported WP donations resulting in 8/10 cases of TT-HBV in the
9 years to the end of 2004, frommore than 25 million blood com-
ponents (unscreened for anti-HBc) transfused [15]. The Irish Hae-
movigilance System (National Haemovigilance Ofﬁce) had not
conﬁrmed any TT-HBV since its inception. However, a single
implicated case could not be excluded (donor untraced, patient
with other risk factors) [13]. In 1999, the prevalence of anti-
HBc in the Republic of Ireland was estimated at 0.51% in the gen-
eral population [12]. When anti-HBc screening was initiated in
Irish blood donors, the prevalence in the ﬁrst year of testing
was 0.17% [16]. In 60 anti-HBc reactive donations identiﬁed in
the ﬁrst 120,000 donations tested none contained detectable
HBV DNA (personal communication Dr. Joan O’ Riordan). The
blood components received by the index patient had been
screened with the most sensitive HBsAg assay and anti-HBc and
the likelihood of having transmitted HBV to the recipient was
extremely low.
The alternative explanation of reactivation is well docu-
mented by concordant epidemiological and molecular evidence.
The index patient had experienced acute hepatitis in 1975. The
probability of having acquired HBV infection through heterosex-
ual contact is high since his spouse was likely to have been a then
carrier of HBV as not only the index patient but also their ﬁrst-
born child were infected. The spouse apparently seroconverted
to anti-HBs after years of carriage (Table 1) so that strong but
only indirect evidence of infectivity was obtained. However, the
proven chronic carrier status of the brother-in-law (Patient 1,
Table 1) and the phylogenetic link between Patient 1 and the
index patient seem to implicate the index patient’s spouse in
his initial infection (Fig. 1). The sharing of the same genotype D
and subgenotype D3 by the index patient and Patient 1 (In Ire-
land genotype A2 is dominant) is not particularly informative
since the blinded unrelated individual examined (Patient 2) also
carried genotype D although subgenotype D1 and there is evi-
dence that this genotype is increasing in proportion (32%) in
the southern part of the country [17]. Fig. 1 indicates some relat-
edness of nucleotide sequences covering half of the viral genome
between the index patient and Patient 1, more so than with other
genotype D available sequences including Patient 2. However,
these two sequences have substantial divergence and unrelated
sequences of HBV subgenotype 3 available in GenBank appear
in the same cluster with 83% bootstrap value (Fig. 1). Such genetic
distance is not particularly surprising since Patient 1 and his sis-
ter’s strains have evolved with high-level replication (viral loadJournal of Hepatology 201>10E5 in 2004) for 20 years until the index patient was infected
and Patient 1 strain further evolved for 30 years after the index
patient infection. However, although the homology between the
two sequences is 98.2%, the phylogenetic analysis is compatible
with but does not formally proved genetic relatedness. In addi-
tion, the reactivated strain replicating in the index patient was
submitted to considerable immune pressure related to the pres-
ence of anti-HBs probably generated by the vaccination 1.5 years
prior to the acute episode and by the likely stimulation of the
patient’s own memory B-cells triggered by the vaccine antigen
(Fig. 2).
Reactivation of HBV in the index patient is supported by the
elevation of ALT levels prior to October 2004 and a peak of ALT
concomitant with the occurrence of HBsAg. Although infection
through another route cannot be formally excluded, the genetic
data is compatible with a relatively mild acute hepatitis caused
by a host-selected endogenous escape mutant. Reactivation of
HBV in the presence of anti-HBs has been described in recipients
of organ transplantation [18–21] hematology patients [2,6]
including two cases with CLL treated with Fludarabine [22] and
breakthrough infections in vaccinated individuals are not excep-
tional [23–25]. However, the combination of single chemother-
apy-induced reactivation and breakthrough escape mutant has
not been described. One case anti-HBs positive receiving multiple
drug chemotherapy reactivated by selecting a mutant of cysteine
137 associated with G145R [26]. The mutations found in the
index patient, in particular the substitution of the cysteine at
codon 139 of the S gene (Fig. 2) was not observed post-vaccina-
tion or described in other circumstances except occult HBV infec-
tion (OBI). The associated mutations in loops 1 and 3 have been
previously described. Loop 1 P120S was observed in at least eight
cases of vaccinated or passively immunized patients [24,26–28].
Mutation G130R was identiﬁed in at least three cases, one of
them in a genotype D strain [26,29,30]. Codon 134 is genotype
speciﬁc, phenylalanine in genotypes A, B, and C and Tyrosine in
genotype D strains [26].
The nearly undetectable anti-HBs only 18 months after vacci-
nation in a previously exposed individual might be related to part
of the anti-HBs complexed with viral antigen produced in small
amounts but still recognized by the circulating anti-HBs. Only
when the escape mutant emerged with high level of replication
reactivation became clinically recognizable. The escape mutant
hypothesis is further supported by the lack of detection of the
recombinant mutant protein by three of six commercial HBsAg
assays as well as its poor reactivity with two of three monoclonal
antibodies speciﬁc of HBsAg (Table 2). This was further supported
by the enhanced reactivity of the SDM recombinant protein with
all assays and monoclonal antibodies despite the two substitu-
tions left in the loop 3 region (Table 2). This data is strong evi-
dence of the critical importance of cysteine 139 in the
conformation and presentation of the ‘a’ determinant to mono-
clonal antibodies used in the commercial HBsAg assays. It also
suggests that the selection of the mutated cysteine 139 by the
patient anti-HBs played a signiﬁcant role in the escape
mechanism.
It can be speculated that the immunosuppressive effect of
treatment with Chlorambucil was sufﬁciently mild not to disturb
immunological control over the probably very few viral particles
persistent in the index patient liver. Such mild effect has been
demonstrated in a large randomized trial comparing the reactiva-
tion of HSV and CMV in patients treated for lymphoma with0 vol. 53 j 780–787 785
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Chlorambucil alone, Fludarabine alone or both drugs [31]. The
higher degree of immunosuppression induced by Fludarabine
triggered reactivation but, probably in relation with the presence
of neutralizing anti-HBs, took approximately 1 year of treatment-
induced viral replication to select a variant able to escape these
antibodies. In a study of Fludarabine-induced HBV reactivation
without anti-HBs, HBsAg became detectable after a few months
of treatment [32]. The pathogenic impact of this mutant was
probably limited (relatively low level of ALT and short duration
of detectable HBsAg) by the ability of the stimulated immune sys-
tem to adapt to this new antigen.
This case strongly suggests that patients should be screened
for serological hepatitis markers in advance of instituting Fludar-
abine therapy and an archive sample should be retained. Such
screening could lead to prevention or control by early antiviral
therapy of reactivation in the patient and reduction of the need
for onerous look-back investigations of suspected TT-HBV, espe-
cially as this risk is extremely low and look-back traumatic for
donors [33].
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